Demographic and disease characteristics of fully vaccinated* individuals with rheumatic disease diagnosed with SARS-CoV-2 infection after vaccination reported to the C19-GRA registry (n=87)
| Frequency (%) or mean (SD) | |
| Mean age (years), SD | 53.8 (16.3) |
| Female | 67 (77) |
| Race or ethnicity | |
| White | 49 (56.3) |
| Black | 6 (6.9) |
| Latin American | 10 (11.5) |
| East or South Asian | 7 (8.1) |
| Other | 9 (10.3) |
| Unknown | 6 (6.9) |
| WHO regions | |
| African region | 2 (2.3) |
| Region of the Americas - North | 65 (74.7) |
| Region of the Americas - South | 1 (1.2) |
| South-East Asian region | 0 (0) |
| European region | 8 (9.2) |
| Eastern Mediterranean region | 7 (8.1) |
| Western Pacific region | 4 (4.6) |
| Rheumatic disease† | |
| Rheumatoid arthritis | 34 (39.1) |
| Systemic lupus erythematosus | 10 (11.5) |
| Psoriatic arthritis | 12 (13.8) |
| Vasculitis | 10 (11.5) |
| Inflammatory myopathy | 8 (9.2) |
| Spondyloarthritis (axial and other) | 3 (3.5) |
| Sjogren’s syndrome | 4 (4.6) |
| Systemic sclerosis | 4 (4.6) |
| Other‡ | 8 (9.2) |
| Comorbidity count | |
| 0 | 46 (52.9) |
| 1 | 26 (29.9) |
| ≥2 | 15 (17.2) |
| Most common comorbidities | |
| Hypertension | 24 (27.6) |
| Obesity | 18 (20.7) |
| Lung disease | 16 (18.4) |
| Diabetes | 9 (10.3) |
| Chronic kidney disease | 8 (9.2) |
| Medication prior to COVID-19 diagnosis§ | |
| No DMARD | 6 (6.9) |
| csDMARDs | 57 (65.5) |
| Methotrexate | 21 (24.1) |
| Hydroxychloroquine | 25 (28.7) |
| Leflunomide | 6 (6.9) |
| Azathioprine | 6 (6.9) |
| Mycophenolate | 10 (11.5) |
| Sulfasalazine | 4 (4.6) |
| Colchicine | 2 (2.3) |
| b/tsDMARDs | 51 (58.6) |
| B cell-depleting therapy | 16 (18.4) |
| TNF inhibitors | 19 (21.8) |
| Other biologics¶ | 10 (11.5) |
| JAK inhibitors | 6 (6.9) |
| Glucocorticoid dose | |
| 0 mg/day | 61 (70.1) |
| 1–9 mg/day | 18 (20.7) |
| ≥10 mg/day | 6 (6.9) |
| Missing/unknown | 2 (2.3) |
| Disease activity | |
| Remission/low | 69 (79.3) |
| Moderate/high | 18 (20.7) |
| Confirmed COVID-19** | 87 (100) |
| Vaccine | |
| Pfizer-BioNTech | 45 (51.7) |
| Moderna | 21 (24.1) |
| AstraZeneca/Oxford | 6 (6.9) |
| Sinovac | 5 (5.7) |
| Janssen/Johnson & Johnson | 6 (6.9) |
| Don’t know/missing | 4 (4.6) |
*Fully vaccinated: infection ≥14 days after second dose of a two-dose vaccine or first if Janssen/Johnson & Johnson.
†Cases could have more than one disease diagnosis.
‡Other rheumatic diseases include mixed connective tissue (n=2), antiphospholipid antibody syndrome (n=1), autoinflammatory syndrome (n=1), IgG4-related disease (n=1), undifferentiated connective tissue disease (n=1), Still’s disease (n=1) and palindromic rheumatism (n=1).
§csDMARD medications included antimalarials (hydroxychloroquine, chloroquine), azathioprine, cyclophosphamide, ciclosporin, leflunomide, methotrexate, mycophenolate mofetil/mycophenolic acid, sulfasalazine and tacrolimus; b/tsDMARD included abatacept, belimumab, CD20 inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, anti-TNF and Janus kinase inhibitors.
¶Other biologics include abatacept (n=4), IL-6 (n=2), IL-1 (n=2), belimumab (n=1) and ustekinumab (n=1).
**Confirmed COVID-19 diagnosis: diagnosis made via PCR, antigen or antibody test.
††
BMI, body mass index; b/tsDMARD, biologic/targeted synthetic disease-modifying antirheumatic drugs; C19-GRA, COVID-19 Global Rheumatology Alliance; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; DMARD, disease-modifying antirheumatic drugs; JAK, Janus kinase; TNF, tumor necrosis factor.